COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efalizumab in the Treatment of Alopecia, Phase II

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00746980
Recruitment Status : Withdrawn (Newly identified safety concerns have changed the risk and benefit considerations)
First Posted : September 4, 2008
Last Update Posted : June 14, 2016
Genentech, Inc.
Information provided by (Responsible Party):
Dennis West, Northwestern University

Brief Summary:
Determine the effect that treatment with efalizumab has on scalp hair re-growth in younger adults affected by severe variants of alopecia areata, including alopecia totalis, alopecia universalis, and severe ophiasis variants.

Condition or disease Intervention/treatment Phase
Alopecia Totalis Drug: efalizumab Phase 2

Detailed Description:
This is a Phase II trial (single-center, open-label, prospective study) where subjects with severe forms of alopecia areata, namely alopecia totalis, universalis, and severe ophiasis, will be treated with efalizumab (Raptiva), a humanized monoclonal anti-CD11a antibody that reversibly inhibits T cell activation and migration, weekly for 48 weeks. We will assess for effect on hair and body re-growth as well as record any serious adverse events such as serious infections, thrombocytopenia, development of malignancy, and severe arthralgias to monitor for safety outcome data. Subjects will have regular physical examinations and laboratory studies throughout the study, as well as telephone interviews.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efalizumab in the Treatment of Alopecia Totalis/Universalis in Young Adults, Phase II
Study Start Date : August 2008
Estimated Primary Completion Date : July 2009
Estimated Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment
Subjects receiving drug
Drug: efalizumab
1 mg/kg subcutaneously once weekly for 48 weeks, following an initial conditioning dose of 0.7 mg/kg at week 0.
Other Name: Raptiva

Primary Outcome Measures :
  1. Percentage re-growth of scalp hair loss [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Self-assessment (SA) and Static physician global assessment (SPGA) [ Time Frame: 1 year ]
  2. Body hair re-growth at 48 weeks [ Time Frame: 1 year ]
  3. Quality of life questionnaire [ Time Frame: 48 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ability to provide written informed consent and comply with study assessments for the full duration of the study.
  • clinical diagnosis of alopecia totalis, alopecia universalis, or severe ophiasis variant of alopecia areata.
  • 18-40 years of age.
  • if a female of childbearing potential, a negative pregnancy test and commitment to the use of two forms of effective contraception (birth control) for the duration of the study are necessary.
  • if a non-sterile male, commitment to the use of two forms of effective contraception (birth control) for the duration of the study is necessary.

Exclusion Criteria:

  • known hypersensitivity to efalizumab (Raptiva) or any of its components.
  • known liver disease, including active hepatitis
  • history of autoimmune diseases causing alopecia other than alopecia areata.
  • prior biologic therapy within 6 months prior to study initiation.
  • history of any malignancy within last ten years, except treated non-melanoma skin cancers.
  • any woman currently pregnant or lactating.
  • intake of systemic immunosuppressive agents, including oral corticosteroids, within 3 months prior to study initiation.
  • history of positive PPD and/or tuberculosis.
  • history of HIV/AIDS
  • prior enrollment in any efalizumab study
  • any condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.
  • participation in another simultaneous clinical trial involving investigational agents.
  • positive HIV screening test obtained at screening visit.
  • positive QuantiFERON-TB test obtained at screening visit.
  • positive hepatitis screen obtained at screening visit.
  • platelet count 150 x 10(9)/L at baseline visit.
  • presence of any abnormal laboratory value obtained at screening visit assessed as clinically significant by principal investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00746980

Sponsors and Collaborators
Northwestern University
Genentech, Inc.
Layout table for investigator information
Principal Investigator: Dennis West, PhD Northwestern University, Department of Dermatology
Layout table for additonal information
Responsible Party: Dennis West, Professor in Dermatology and Pediatrics, Northwestern University Identifier: NCT00746980    
Other Study ID Numbers: 20070823
First Posted: September 4, 2008    Key Record Dates
Last Update Posted: June 14, 2016
Last Verified: June 2016
Keywords provided by Dennis West, Northwestern University:
Additional relevant MeSH terms:
Layout table for MeSH terms
Alopecia Areata
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical